Polypill for cardiovascular disease prevention.

Polypill for cardiovascular disease prevention.

Detaylı Bibliyografya
Yazar:	Dalton, A
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2013

Benzer Materyaller

The Concept of the Polypill in the Prevention of Cardiovascular Disease
Yazar:: Brandon Wiley, ve diğerleri
Baskı/Yayın Bilgisi: (2014-04-01)

Polypills with or without aspirin for primary prevention of cardiovascular disease
Yazar:: Mant, J, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

The feasibility of polypill for cardiovascular disease prevention in Asian Population
Yazar:: Apichard Sukonthasarn, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease
Yazar:: J. Masjuan, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

Medicinal herbs: Potential polypills in cardiovascular diseases
Yazar:: Samaneh Noroozi, ve diğerleri
Baskı/Yayın Bilgisi: (2021-04-01)

Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis
Yazar:: Omneya A. Kandil, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

The polypill: the solution for prevention of coronary heart disease?
Yazar:: Hendarto Natadidjaja
Baskı/Yayın Bilgisi: (2016-02-01)

THE ROLE OF POLYTABLETS (POLYPILL) IN THE TREATMENT OF CHRONIC CARDIOVASCULAR DISEASES
Yazar:: Николай Владимирович Абрамов, ve diğerleri
Baskı/Yayın Bilgisi: (2024-02-01)

Polypill versus medication monotherapy in the prevention of cardiovascular diseases in Iran: An economic evaluation study
Yazar:: Ramin Ravangard, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
Yazar:: Lilian Grigorian-Shamagian, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

The use of polypills in cardiovascular disease management: Benefits vs challenges
Yazar:: Yamaan Adil, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
Yazar:: Lopez-Lopez JP, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization
Yazar:: Gunaratne Padma S, ve diğerleri
Baskı/Yayın Bilgisi: (2011-01-01)

A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries
Yazar:: Gautam Satheesh, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Redefining the polypill: pros and cons in cardiovascular precision medicine
Yazar:: Siddharth Birla, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

Exercise Rehabilitation in Heart Disease: the real “polypill” for primary and secondary prevention
Yazar:: Massimo F. Piepoli
Baskı/Yayın Bilgisi: (2005-06-01)

Correction: A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries
Yazar:: Gautam Satheesh, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Preventing the progression of climate change: one drug or polypill?
Yazar:: Hugh Montgomery
Baskı/Yayın Bilgisi: (2017-03-01)

Polypill holds promise for people with chronic disease
Yazar:: Jacqui Wise
Baskı/Yayın Bilgisi: (2005-12-01)

Polypill" conception in modern cardiology
Yazar:: I E Chazova, ve diğerleri
Baskı/Yayın Bilgisi: (2018-12-01)

Polypill revisited – Unity in diversity
Yazar:: Gheorghe-Andrei Dan, ve diğerleri
Baskı/Yayın Bilgisi: (2020-08-01)

Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study
Yazar:: Carlos Aguiar, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.
Yazar:: Reza Jahangiri, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study
Yazar:: Cordero A, ve diğerleri
Baskı/Yayın Bilgisi: (2023-07-01)

Three-dimensional printing of flexible polypill
Yazar:: Yasir Karkar, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease
Yazar:: Jowett, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
Yazar:: Sue Jowett, ve diğerleri
Baskı/Yayın Bilgisi: (2017-01-01)

Polypill Brings Benefits to Patients with Cardiovascular Disease, Both Improving Medication Adherence and Demonstrating the Concept of Chronotherapy [Letter]
Yazar:: Zhu LL, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

The Benefits of Polypill: Adherence and Chronotherapy [Response to Letter]
Yazar:: Lopez-Jaramillo P, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Has the polypill finally proven its worth?
Yazar:: Treadwell, J
Baskı/Yayın Bilgisi: (2019)

Inclusion of Polypills for Prevention of Cardiovascular Disease in the 23rd World Health Organization Model List of Essential Medicines: A Significant Step Towards Reducing Global Cardiovascular Morbidity and Mortality
Yazar:: Anubha Agarwal, ve diğerleri
Baskı/Yayın Bilgisi: (2024-02-01)

The cardiovascular polypill as baseline treatment improves lipid profile and blood pressure regardless of body mass index in patients with cardiovascular disease. The Bacus study.
Yazar:: José Alejandro Chávez Fernández, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk
Yazar:: Usherwood Tim, ve diğerleri
Baskı/Yayın Bilgisi: (2010-08-01)

Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study
Yazar:: Virdee, S, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Effect of a Cardiovascular Polypill on Poststroke Cognition Among Ghanaians: Secondary Analysis of a Randomized Clinical Trial
Yazar:: Fred Stephen Sarfo, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Randomized Polypill crossover trial in people aged 50 and over.
Yazar:: David S Wald, ve diğerleri
Baskı/Yayın Bilgisi: (2012-01-01)

Polypill therapy and frailty in elderly: Time to stop treating everything
Yazar:: Sunil Kumar, ve diğerleri
Baskı/Yayın Bilgisi: (2021-04-01)

The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials.
Yazar:: C Raina Elley, ve diğerleri
Baskı/Yayın Bilgisi: (2012-01-01)

Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia
Yazar:: Hae Won Jung, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.
Yazar:: PILL Collaborative Group, ve diğerleri
Baskı/Yayın Bilgisi: (2011-01-01)